Veenendaal, November 24th, 2021 – MolGen B.V.is a global solutions provider of innovative DNA / RNA extraction technology, system, products and kits for human and animal diagnostics, agriculture, aquaculture, pharma and biotech, is proud to announce that it has recently opened its UK office. The new office is located at 6th Floor, South Quay Building, 189 Marsh Wall, London, E14 9SH. This expansion will enable the company to meet the rapidly increasing demand for cost-efficient, high quality diagnostic services in new markets. The new location will serve as a pivotal branch to provide professional laboratories based in London and the UK with access to MolGen’s innovative extraction DNA / RNA portfolio across diagnostics, pharma and the biotech industry. The opening of this new office comes shortly after MolGen opened its US office in San Diego.
“We have been fortunate to experience such rapid growth as a company. Our ability to scale quickly has been a great asset as we continue to strive to meet the growing demand for our innovations. We see this new office as a way to further advance the testing and diagnostics industry and provide solutions as to how the world responds to disease and other life science conditions,” said Niels Kruize, MolGen CCO.
Anthony Haynes, Managing Director and Greig Pollard, Head of Automation UK
MolGen UK will serve as the launch point for MolGen’s innovative product MegaPrep – a revolutionary bi-weekly, non-invasive monitoring PCR test that gives users the ability to analyse up to a million samples a day. Using more devices that can be customised to each lab, MegaPrep brings precision, speed and quality to the diagnostics workflow, resulting in accurate analysis at scale. As a pay-by-sample testing method it will help more parts of society, such as schools and business to remain open and combat disease. With MegaPrep, MolGen UK will forge the future of testing capacity by extending the workflow with monitoring that involves low cost, high-frequency testing and delivers peace of mind to all.